Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oncogene

Showing results (521-530 of 22,557) with videos related to

Pageof 2,256
Sort By:
Oncogene|November 30, 2006
HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6APA Shai, M L Nguyen, J Wagstaff, et al.
Oncogene|November 30, 2006
Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasionS A Mehta, K W Christopherson, P Bhat-Nakshatri, et al.
Oncogene|November 30, 2006
PLC gamma contributes to metastasis of in situ-occurring mammary and prostate tumorsC R Shepard, J Kassis, D L Whaley, et al.
Oncogene|November 30, 2006
Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cellsG Hawcroft, C W S Ko, M A Hull
Oncogene|November 30, 2006
The codon 72 polymorphism-specific effects of human p53 are absent in mouse cells: implications on generation of mouse modelsB H Phang, K Sabapathy
Oncogene|November 30, 2006
eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migrationA Amiri, F Noei, S Jeganathan, et al.
Oncogene|November 30, 2006
Serine protease Omi/HtrA2 targets WARTS kinase to control cell proliferationS Kuninaka, S-I Iida, T Hara, et al.
Oncogene|December 19, 2006
Functional implication of BMP4 expression on angiogenesis in malignant melanomaT Rothhammer, F Bataille, T Spruss, et al.
Oncogene|December 19, 2006
An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activationY Fan, C Gélinas
Oncogene|December 19, 2006
Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylateO Kosmider, N Denis, P Dubreuil, et al.
Pageof 2,256

Showing results (521-530 of 22,557) with videos related to

Sort By:
Pageof 2,256
Oncogene|November 30, 2006
HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6APA Shai, M L Nguyen, J Wagstaff, et al.
Oncogene|November 30, 2006
Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasionS A Mehta, K W Christopherson, P Bhat-Nakshatri, et al.
Oncogene|November 30, 2006
PLC gamma contributes to metastasis of in situ-occurring mammary and prostate tumorsC R Shepard, J Kassis, D L Whaley, et al.
Oncogene|November 30, 2006
Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cellsG Hawcroft, C W S Ko, M A Hull
Oncogene|November 30, 2006
The codon 72 polymorphism-specific effects of human p53 are absent in mouse cells: implications on generation of mouse modelsB H Phang, K Sabapathy
Oncogene|November 30, 2006
eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migrationA Amiri, F Noei, S Jeganathan, et al.
Oncogene|November 30, 2006
Serine protease Omi/HtrA2 targets WARTS kinase to control cell proliferationS Kuninaka, S-I Iida, T Hara, et al.
Oncogene|December 19, 2006
Functional implication of BMP4 expression on angiogenesis in malignant melanomaT Rothhammer, F Bataille, T Spruss, et al.
Oncogene|December 19, 2006
An optimal range of transcription potency is necessary for efficient cell transformation by c-Rel to ensure optimal nuclear localization and gene-specific activationY Fan, C Gélinas
Oncogene|December 19, 2006
Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylateO Kosmider, N Denis, P Dubreuil, et al.
Pageof 2,256